Targeting replication stress to boost immune therapy in small cell lung cancer
Official title: Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
Funded at Ohio State University · NIH-11391332 · Data updated 2026-11-12
A doctor-scientist team at Ohio State University is testing a new approach to make immune checkpoint therapies work better for people with small cell lung cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 1, 2021 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $13,201 |
| NIH project number | 7R01CA258784-06 |
| Project ID | NIH-11391332 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with small cell lung cancer who may benefit from new immunotherapy combinations.
✕Less likely to help
Patients whose tumors do not express targets affected by replication stress pathways may see limited benefit.
What this research studies
This project explores how blocking replication stress responses in cancer cells may enhance the body’s immune attack when combined with existing immunotherapies. The researchers will study how inhibiting replication stress changes PD-L1 and innate immune pathways, potentially making tumors more visible to T cells. They will use cell and animal models to understand mechanisms and identify opportunities to translate findings to patients. The goal is to develop immunotherapy strategies that can be moved into clinical testing for better patient outcomes.
Why it matters
Potential benefit: If successful, the approach could make immunotherapies work more effectively for patients with small cell lung cancer.
How similar studies have gone: Preclinical evidence suggests that targeting replication stress can modulate immune responses and improve therapy in cancer models.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Sen, Triparna — Ohio State University
- Study coordinator: Sen, Triparna
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.